1. Home
  2. MAGN vs DSGN Comparison

MAGN vs DSGN Comparison

Compare MAGN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnera Corporation

MAGN

Magnera Corporation

HOLD

Current Price

$14.54

Market Cap

521.2M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.72

Market Cap

504.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAGN
DSGN
Founded
1864
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
521.2M
504.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MAGN
DSGN
Price
$14.54
$9.72
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$16.00
$13.50
AVG Volume (30 Days)
930.3K
504.3K
Earning Date
02-05-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,204,000,000.00
N/A
Revenue This Year
$5.74
N/A
Revenue Next Year
$2.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
46.50
N/A
52 Week Low
$7.82
$2.60
52 Week High
$23.19
$10.31

Technical Indicators

Market Signals
Indicator
MAGN
DSGN
Relative Strength Index (RSI) 64.64 58.56
Support Level $14.56 $8.43
Resistance Level $15.20 $10.11
Average True Range (ATR) 0.48 0.68
MACD -0.13 -0.06
Stochastic Oscillator 56.29 66.07

Price Performance

Historical Comparison
MAGN
DSGN

About MAGN Magnera Corporation

Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: